Australia | Europe | Israel | Japan | Latin America | Canada and the United States | Total | |
---|---|---|---|---|---|---|---|
Seroprevalence of CMV IgG by sex, % (95% CIa) | |||||||
NR | 39.3 (34.9–43.8) | NR | NR | NR | 48.0b | 39.3–48.0 | |
Women of reproductive age [32, 34,35,36,37,38,39,40,41,42,43,44,45,46,47] | NR | 45.6–95.7 | NR | 60.2b | 58.3–94.5 | 24.6–81.0 | 24.6–95.7 |
NR | 94.6b | NR | NR | 86.5b | NR | 86.5–94.6 | |
NR | 58.5–94.9 | NR | NR | 91.3b | 54.4b | 54.4–94.9 | |
NR | 62.3–95.7 | NR | NR | NR | 40.0–59.7% | 40.0–95.7 | |
NR | 87.7b | NR | NR | NR | 69.8b | 69.8–87.7 | |
Seroprevalence of CMV IgM by sex, % (95% CIa) | |||||||
Mend | NR | NR | NR | NR | NR | NR | NR |
NR | 1.0–4.6 | NR | 0.8b | 0.0–0.7 | 2.3–4.5 | 0.0–4.6 | |
NR | 1.0–2.0 | NR | NR | NR | 4.5b | 1.0–2.0 | |
NR | 2.8b | NR | NR | NR | 2.3b | 2.3–2.8 | |
Aged 40–50 yearsc [45] | NR | NR | NR | NR | NR | 2.4b | 2.4 |
Seroprevalence of CMV IgG by age, % (95% CIa) | |||||||
Adults (≥ 19 years) [32, 33, 35,36,37, 40,41,42, 44,45,46,47,48,49,50,51,52,53,54,55] | NR | 44.4–95.7 | NR | 67.2–70.9 | 59.1–91.3 | 33.0–81.0 | 33.0–95.7 |
NR | 64.5–97.7 | NR | NR | NR | NR | 64.5–97.7 | |
Age intervals | |||||||
NR | 70.3–94.6 | NR | NR | 86.5b | 47.3b | 47.3–94.6 | |
NR | 58.5–94.9 | NR | NR | 91.3b | 54.4b | 54.4–94.9 | |
NR | 62.3–95.7 | NR | NR | NR | 40.0–59.7 | 40.0–95.7 | |
NR | 85.3–87.7 | NR | NR | NR | 67.0–69.8 | 67.0–87.7 | |
NR | 91.5 (87.8–94.4) | NR | NR | NR | 61.0b | 61.0–91.5 | |
NR | 64.5–97.7 | NR | NR | NR | NR | 64.5–97.7 | |
Seroprevalence of CMV IgM by age, % (95% CIa) | |||||||
NR | 1.0–6.7 | NR | NR | NR | 2.3–4.5 | 1.0–6.7 | |
Elderly (≥ 60 years) [51] | NR | 3.5 (1.7–6.3) | NR | NR | NR | NR | 3.5 (1.7–6.3) |
Age intervals | |||||||
12–19 yearsc [45] | NR | NR | NR | NR | NR | 2.6b | 2.6 |
NR | 1.0–6.7 | NR | NR | NR | 4.5b | 1.0–6.7 | |
NR | 2.4–2.8 | NR | NR | NR | 2.3b | 2.3–2.8 | |
NR | 4.3 (2.3–7.4) | NR | NR | NR | 2.4b | 2.4–4.3 | |
50–60 yearsc [51] | NR | 4.3 (2.3–7.2) | NR | NR | NR | NR | 4.3 (2.3–7.2) |
60–100 yearsc [51] | NR | 3.5 (1.7–6.3) | NR | NR | NR | NR | 3.5 (1.7–6.3) |
CMV shedding by age (regardless of diagnostic method), % (95% CIa) | |||||||
Newborns/infants [48] | NR | 0.0b | NR | NR | NR | NR | 0.0b |
Newborns/infants to adolescents | NR | NR | NR | NR | NR | NR | NR |
NR | 11.0–51.9 | NR | NR | NR | 17.0b | 11.0–51.9 | |
Children [48] | NR | 5.2b | NR | NR | NR | NR | 5.2b |
Adolescents [48] | NR | 0.0b | NR | NR | NR | NR | 0.0b |
Adolescents to adults [60] | NR | 70.2b | NR | NR | NR | NR | 70.2b |